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Abstract
Context: The most common cancer and cause of cancer-related death in pregnant and breastfeeding patients is breast cancer. In
the world, the incidence of pregnancy-associated breast cancer (P.A.B.C) is increasing, which is due to the fact that women delay
their pregnancy up to the middle ages. According to the definition of P.A.B.C, a pregnancy-associated breast cancer is a case of breast
cancer that occurs during pregnancy or up to 1 year after delivery. The aim of this paper is to review the clinical findings and novel
imaging methods and findings, which help to diagnose pregnancy-associated breast cancer early.
Evidence Acquisition: We reviewed the papers with subjects of PABC and imaging modalities in PABC by searching the medical
and health databases such as PubMed, Google Scholar, as well as clinical trials.
Results: The most frequent manifestation is a painless mass sensation. The most prevalent pathology of PABC is high-grade ductal
carcinoma. The first diagnostic tool and most sensitive modality of imaging in this disease is ultrasound. Mammography during
pregnancy and lactation is a safe method, which performs in symptomatic patients or in patients with positive ultrasound findings.
MRI is not recommended during pregnancy, but it is completely harmless in breastfeeding patients and it is usually used as the
complementary modality.
Conclusions: Timely diagnosis of PABC requires complete knowledge of clinical symptoms and accurate interpreting of the images
in different diagnostic modalities including mammography, ultrasound, and MRI. It should be noted that delay in diagnosis of PABC
is the most common cause of low survival rate and bad prognosis.
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1. Context
1.1. Incidence of PABC
In Iran, breast cancer is the most frequent cancer and
the fifth cause of death due to malignancies with about
8,500 incident cases per year. Iranian women, when being
diagnosed with breast cancer, are at least 1 decade younger
than the developed countries (1). The most common can-
cer in pregnancy and the most common cause of cancer-
related death in pregnant and breastfeeding women is
breast cancer (2, 3). Statistically, 1 case occurs per 3,000
pregnancies (4).
The incidence of breast cancer in pregnancy is increas-
ing, largely due to delayed pregnancy by the middle age.
Throw the average age of the conflict is 32 to 34 years (4,
5). Pregnancy-associated breast cancer (PABC) is a case of
breast cancer that occurs during pregnancy or up to 1 year
after delivery. It is epidemiologically uncommon and ac-
counts for about 0.2% to 3.8% of all breast cancers (5, 6).
It is noteworthy that these cancers are generally worse in
prognosis and they are often associated with the axillary
lymph nodes metastasis and larger tumor size in diagno-
sis, possibly due to delay in detection (7). According to pre-
vious studies, the prevalence of PABC among mothers who
were first pregnant after 30 years was 2 to 3 times that of the
number of mothers who gave birth to their first children
before the age of 20 (7). Common PABC differential diag-
noses include fibroadenoma, lactation adenoma, galacto-
cele, and fibrocystic changes. Rarer differential diagnoses
are lymphoma, leukemia, and sarcoma.
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2. Evidence Acquisition
We reviewed several published papers on PABC and
imaging modalities in PABC by searching the medical and
health databases such as PubMed, Google Scholar, as well
as clinical trials.
3. Results
3.1. Clinical Manifestations
One of the most common causes of the referral of preg-
nant and lactating patients to breast clinics is mass or
nodularity sensation. During this period, due to hormonal
changes, the volume of fibroglandular tissue, as well as
the volume of water and blood supply increases; so, breast
nodularity in the clinical examinations can make difficul-
ties for both clinical diagnosis and interpretation of differ-
ent imaging techniques. Nodularity sensation by a physi-
cian or patient that lasts more than 2 to 4 weeks should be
seriously taken and necessitates the use of imaging tech-
niques (8). The most common manifestation of PABC is
a painless mass discovered by the physician or patient (4,
9). Other symptoms include unilateral breast enlargement
accompanied by skin thickening, localized pain, and nip-
ple discharge with or without mass or erythema, or even
with distant metastasis and local invasion (10, 11). In some
patients, a less common finding called milk rejection oc-
curs; it means the infant is reluctant to eat milk from the
affected breast. One of the rare symptoms is bloody dis-
charge (12, 13). Histopathology: The most common PABC
pathology in the time of diagnosis is high-grade ductal car-
cinoma with a high incidence of lymphovascular invasion
(14). These tumors are mostly positive hormone receptors
(estrogen and progesterone) compared to those with simi-
lar age and non-PABC. Only 30% of PABCs are HER2-positive
(14, 15). However, in some studies, there is no significance
between PABC and non-PABC in the prevalence of hormone
receptors, p53, and HER2 (16).
3.2. Imaging Modalities
3.2.1. Ultrasound
Ultrasonography in the diagnosis of PABC has a high
sensitivity and specificity (17). The first step in dealing with
pregnant and breastfeeding patients with a sense of mass
is ultrasound. Since in this phase the nodularity of the
breast tissue increases, any sustainability nodularity that
lasts at least more than 2 to 4 weeks requires a Target ul-
trasound. In similar studies, the sensitivity of ultrasound
to detect PABC has been reported to be up to 100% with a
negative predictive value of about 100%. In another study,
sonography was abnormal in 100% of symptomatic pa-
tients (11). Any suspicious mass found in ultrasound should
subsequently be subjected to an ultrasound-guided biopsy.
If the pathology is malignant, it is necessary to carefully
examine the contralateral breast, as well as the multifo-
cal or multicentric lesion in the same breast. It should be
noted that PABC is more likely to be locally advanced. An-
other application of ultrasound in the PABC management
setting is serial mass size measurement after neo-adjuvant
chemotherapy. Sonographic criteria of PABC do not signif-
icantly differ from non-PABC (Figure 1). The most common
finding in ultrasound is mass. Most of these masses tend
to have large cystic parts that can be induced due to their
invasive nature and central necrosis (17, 18). So, it is im-
portant to note that cystic-solid (complex) masses, which
is discovered during pregnancy and lactation, should be
biopsied and should not be abandoned to the abscess or
galactocele unless clinically apparent. Sonographic crite-
ria are helpful in the determination of malignant and be-
nign masses (Figure 1). According to the system of BI-RADS
(breast imaging and data reporting system), ultrasound
specimens including spiculated margin, irregular shape,
and non-parallel orientation are potent malignant sugges-
tions, while the elliptical shape and well-defined margins
are in favor of benign tumors. In pregnancy and lactation,
due to physiological changes in breast tissue, we may not
have typical ultrasonographic views of malignancy. In a
study, 58% of masses with malignant pathology demon-
strated parallel orientation, as we know this is a sign of be-
nign masses (19). Posterior enhancement, which is com-
monly seen in benign lesions, has been reported in 63% of
PABC cases in a study (19). In various papers, biopsy was rec-
ommend for every solid mass, which was discovered in ul-
trasound during pregnancy. One of the other ultrasound
application for PABC, according to NCCN guidelines (2017),
is the evaluation of liver metastasis in patients with PABC,
who are diagnosed with axillary lymph node involvement
or have tumors in the T3 and higher (above 5 cm).
3.2.2. Mammography
Mammography during pregnancy and lactation is a
very safe method, and the use of abdominal shielding si-
multaneously can reduce the amount of radiation by up to
50% (20). Bilateral full-field digital mammography radia-
tion dose is less than 3 milli-grays (21). The scattered dose
of radiation to the uterus is very low (approximately 0.03
mg). It is necessary to recall that teratogenic effects of radi-
ation on the fetus at doses lower than 50 milli-gray are not
yet reported (22). Although mammograms are relatively
harmless in the pregnancy and lactation phase, it is only
recommended in cases with suspicious findings on clinical
examination or ultrasonography (Figure 2) or cases with
a known malignancy (a patient had undergone biopsy).
Mammographic sensitivity for PABC detection is in a range
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Figure 1. A 37-year-old breastfeeding woman 9 months postpartum presented with
a growing tender mass in the upper outer area of right breast: A, ultrasound im-
ages showed a 38*19 mm spiculated, heterogeneous mass with an adjacent satellite
lesion measured12*15 mm in the upper outer portion of the right breast midzone;
B, on ultrasound examination of right axilla, thick cortex axillary lymph nodes with
squeezed hilum are seen; C, after core needle biopsy, invasive ductal carcinoma with
lymph node metastasis was found in the submitted specimens.
of 78% to 90% in the literature (4, 10, 22), which can be due
to hormonal changes and increased breast density. How-
ever, mammography accurately detects suspicious micro-
calcifications (not seen in ultrasound) and multifocal and
multi-centered lesions.
Figure 2. A and B, A 37-year-old breastfeeding woman 9 months postpartum pre-
sented with a growing tender mass in the upper outer area of right breast, on the
obtained CC and MLO view mammographic images in right upper outer quadrant
there is a spiculated irregular shaped mass causing tissue distortion associated with
right axillary lymphadenopathy, metastasis to left axillary lymph nodes causing left
areolar thickening; final histologic report revealed invasive ductal carcinoma.
During breastfeeding before performing mammogra-
phy, it is better to pump breasts. In breastfeeding and preg-
nancy, the routine screening mammogram is not recom-
mended. In women older than 40 years, screening mam-
mography is best avoided until 3 months after lactation,
till the breast parenchyma returns to its original state (23).
In high-risk women such as cases with BRCA muta-
tions, routine screening begins at age of 25 with MRI and
continues with mammography at age of 30. In women
with a high risk of breast cancer during pregnancy, screen-
ing mammography is postponed to 3 months after delivery
(24).
The most common mammographic findings of PABC
include a mass with no accompanying findings, calcifica-
tion, increased skin thickening with increasing parenchy-
mal density, respectively (4, 10, 22), which are similar to
non-PABC. It should be noted that although the suspected
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mass may not be seen on the obtained mammographic
views due to the high density of the breasts, the images
should be carefully evaluated for other signs, such as axil-
lary lymphadenopathy, asymmetric densities, or microcal-
cifications.
3.2.3. MRI
MRI contrast agents during lactation and pregnancy
are categorized as group C according to the FDA (food
and drug administration) classification. Therefore, con-
trast agents are not recommended during pregnancy, al-
though some guidelines such as the European Society of
Urogenital Radiology find this harmless since the proven
teratogenic effects have not been reported in humans (25).
Gadolinium crosses the placenta and some of it is con-
tained in the amniotic fluid by excreting from fetal kid-
neys; hence, the toxic effects of free gadolinium cannot be
ruled out on the fetus (26) routinely intravenous gadolin-
ium should be avoided during pregnancy and used only
if it is judged absolutely essential. Gadolinium may cause
a high blood level in the fetus; this condition in adults
causes the nephrogenic systemic fibrosis (NSF) syndrome.
The probability of this condition in the fetus and infants
under the age of 1 is low due to underdeveloped kidney
function. However, in some academic sources, the use of
gadobenate demeglumine and gadoterate megluminine
(dotareme) are recommended because it has not been re-
ported any case of NSF by injecting these two drugs until
now (8). The national radiological protection board in the
United Kingdom stipulates in its principles for the protec-
tion of patients and volunteers during MRI that it “might
be prudent to exclude pregnant woman during the first
3 months of pregnancy,” whereas the latest American Col-
lege of Radiology guidelines for safe MRI practices does not
differentiate among the pregnancy trimesters, and states
that all pregnant patients could undergo MRI as long as
the benefits outweigh the risks. Because of theoretical con-
cerns, we advocate a cautious approach to using obstet-
rical MRI in the first trimester and in this trimester, MRI
should be restricted to maternal indications (27). There are
no published studies of the long-term effects in children
and significant acoustic impairment resulting from expo-
sure to prenatal MRI even with at magnetic field strengths
of 3 T or more (27). In lactating patients with newly diag-
nosed cancers, MRI with contrast is safe and helps to de-
termine the spread of the disease. Breastfeeding before
obtaining MRI sequences is recommended. It should be
noted that the similarity of lactation changes with sus-
picious findings can reduce the sensitivity of MRI (28).
Gadolinium is secreted very little in milk; however, accord-
ing to the American college of radiology guidelines, it is
not necessary to stop lactation after the contrast injection
(26). By the way, the patient can be depending on his de-
sire, stop breastfeeding for up to 24 hours until Gadolin-
ium is completely removed from milk. For screening of
high-risk patient in lactating phase, MRI has limitations
because of some controversies in the interpretation. Un-
fortunately, little studies about MRI findings of PABC have
been done. In a study of 7 patients in the lactation phase
with the final histological report of PABC, 5 had a clear ap-
pearance of their cancer in T2 without contrast that could
be due to increasing water content of fibroglandular tis-
sue causing increase the intensity of T2 (21). In surveys,
MRI images of PABC have been reported similar to those
of non-PABC, and the most common findings are masses
with homogeneous, heterogeneous, or rim enhancement
as well as nonmass lesions with segmental enhancement
or one-sided diffuse enhancement. Lactation agents, un-
like non-PABC, have a rapid parenchymal background en-
hancement with the type B kinetic curve (early plateau en-
hancement), which may be misleading to malignancy, al-
though malignancies usually show more rapid and severe
enhancement. MRI is important in detecting the spread of
disease (21, 28).
3.3.4. Staging of PABC
In the process of staging, modalities with radiation are
reasonable if they are effective in the management of the
disease, otherwise it is best to avoid them. Ionizing radia-
tion can damage the fetus’s DNA directly or through free
radicals. Radiation complications include mental retarda-
tion and organ malformation that are more common in
conventional radiology and occur at higher doses of 0.2
Gy (23). The most frequent encountered organs involved
in metastasis are the liver, lung, and skeletal system, rou-
tinely staging with chest x-ray, liver ultrasound, bone scan,
or bone MRI without contrast. A chest x-ray with fetus
shielding can be done safely in pregnancy. The preferred
method of diagnosis of metastatic according to NCCN 2016
is non-contrast MRI. A bone scan is applicable only in cases,
where the patient has undetectable MRI findings. In the
evaluation of diagnostic methods, sentinel lymph node
biopsy is not recommended for less than 30 weeks preg-
nancy and it is contraindicated to perform with iso-sulfan-
blue and methylene blue. There are few case studies that
explain the association between the use of tracer radioac-
tive materials and fetus anomalies. PET scan is not indi-
cated in staging (8). The risk of metastasis is approximately
0.9% when cancer diagnosed with 1 month delay and this
risk is 2.6% and 5.1% in the delay of 3 months and 6 months,
respectively, if considering the doubling time of the mass
130 days (24). On the other hand, if the doubling time of the
mass is 65 days, the estimated metastatic risk of these num-
bers increases by 1.8%, 5.2%, and 10.2% for 1, 3, and 5 months,
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respectively (29). Finally, in young patients with PABC in
pregnancy, 48% of cases have positive familial history, 2%
to 29% are with BRCA1 and BRCA2 mutations; therefore, in
PABC cases, genetic counseling is recommended (30, 31).
4. Imaging-Guided Interventions
When a suspicious lesion is discovered in ultrasound,
the basic diagnostic tool is US-guided core needle (14 G)
biopsy. For lesions detected only in mammography, the
stereotactic biopsy could be performed and it is harmless
during pregnancy and lactation. MRI guided biopsy can
also be done in breastfeeding. Before starting the proce-
dure, the patient should ensure that local anesthetic with
subcutaneous lidocaine during pregnancy and lactation
does not cause any problem for the fetus. It should be
noted that due to the increased vascularity of the breast
and dilation of the milk ducts in this phase, the risk of
bleeding and infections is increased (28). One of the rare
complications of biopsy is milk fistula.
5. Conclusions
Nowadays, most women delay their pregnancy until
middle age and the prevalence of PABC is increasing. Ul-
trasound is a selective approach to examining any pal-
pable abnormalities in pregnant and lactating mothers.
Subsequently, the detection of any solid or complex mass
needs further investigation with biopsy. Further evalua-
tion with bilateral mammography should be performed
in patients with suspicious findings in ultrasound. The
mammogram can detect malignant microcalcifications
and some hidden abnormalities. It should be noted that
even if no abnormality discovered in sonogram or mam-
mogram biopsy should be performed from the region of
persistent palpable nodularity or thickening. Delay in de-
tecting PABC has significant clinical effects on patient’s sur-
vival rate.
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